Meet Cybrexa’s leadership team built on deep experience in oncology drug development, clinical trials, and company growth. Together, we are developing the next generation of cancer therapeutics and advancing the future of cancer treatment. https://t.co/iAnzZ6iPEH
Cybrexa’s alphalex™- enabled peptide-drug conjugates bypass traditional therapy limits by targeting universal tumor biology. Our antigen-agnostic approach means more patients with cancer may benefit from treatment, regardless of specific tumor markers. https://t.co/mcEneseAh4
Cybrexa Therapeutics presented new preclinical data at #ESMOTAT25 showing alphalex™ peptide-drug conjugates achieved robust efficacy across multiple tumor models, both as monotherapy and in combination with standard treatments. Read the full results here: https://t.co/b7xVBwxs3p
Cybrexa will present new preclinical findings at #ESMOTAT25 on the potential of alphalex™ peptide-drug conjugates to achieve tumor-selective delivery while minimizing off-target effects.
📅 March 3 | ⏰ 5:15-6:15 PM CET | 🎤 Vishwas Paralkar, Ph.D.
https://t.co/FF5t82FTWT
In a robust Phase 1 trial, our lead clinical-stage program, CBX-12, showed compelling safety & efficacy across six tumor types. With activity confirmed, even in heavily pretreated patients, we are advancing CBX-12 into Phase 2 trials. https://t.co/UkukqrSwRK
#biotech
Our alphalex™ tumor-targeting peptide platform leverages the acidic microenvironment found in all solid tumors, enabling precise delivery of potent therapies where they’re needed most. Explore our science: https://t.co/mcEneseAh4
#biotech
Just announced: The first patient has been dosed with CBX-12 in a Phase 2 trial in women with platinum-resistant or refractory #ovariancancer who are naïve to TOP1-targeted therapies. Learn more at https://t.co/8AQ9956zpj. #biotech#oncology#clinicaltrials
We announced final results from our Phase 1 study of CBX-12 in advanced solid tumors, which showed broad activity across 6 tumor types, including strong response rates in TOP1-naive patients with ovarian and breast #cancer.
Read more: https://t.co/XlFdkkRktW #ESMO24#biotech
We look forward to presenting full results from our Phase 1 study of peptide drug conjugate CBX-12 in advanced solid tumors at @myESMO.
Join us at 12pm CET on Sept 14 to learn more: https://t.co/JThLIyNsb9
#oncology#ESMO24#biotech
#Cybrexa is revolutionizing #cancertherapeutics with its innovative alphalex™ platform, aiming to deliver drugs directly into cancer cells. Stay tuned for exciting clinical updates. https://t.co/1ptR6511FQ.
#peptidedrugconjugates#oncology
#DYK: #Cybrexa & most of our team are HQ’d in #CT, but some of us live in FL, GA, MA, NH, NJ, RI & TX. Despite the distance, Cybrexa’s commitment to raising awareness for various cancers unites our team. Last month, we wore teal ribbons on #WorldOvarianCancerDay. Check us out 👇!
Join us at the ADC Payload Summit in Boston next week for a discussion on #Cybrexa's tumor-selective alphalex™ platform by our CSO Vish Paralkar. Check out the conference agenda here 👉: https://t.co/WTjJgYsiWB.
Today is #WorldOvarianCancerDay. Do you know the symptoms of #ovariancancer?
Repost our video to help spread the word and raise vital awareness. For more information about ovarian cancer symptoms, visit our website 👉 https://t.co/KCPIEJRsjh
#NoWomanLeftBehind#WOCD2024
Meet Lindsey Clapes, Office Manager at #Cybrexa. W/ 10+ yrs exp in biotech/pharma, Lindsey oversees the travel program, organizes team events, leads community outreach & keeps track of the boss. She enjoys the startup environment & progression of science. #EmployeeSpotlight
Happy #WorldLaboratoryDay! At Cybrexa, our lab team is working hard to develop new #cancertherapeutics with the potential to improve pts' lives. Learn about our mission & the incredible work we are doing to transform the future of #oncolgy 👉 https://t.co/V262bvnOIi.